Neurology/Psychiatric Lucid-21-302 shows promise in preclinical studies of multiple sclerosis Feb. 28, 2023 Current therapies for multiple sclerosis (MS) focus on targeting immunomodulatory mechanisms...Read More
Neurology/Psychiatric Canadian clearance for phase I trial of Lucid-MS for multiple sclerosis Feb. 8, 2023 FSD Pharma Inc. has received a no objection letter (NOL) from Health Canada granting regulatory approval to commence a phase I trial of LUCID-21-302 (Lucid-MS), a novel drug candidate for the treatment of multiple sclerosis (MS).Read More
